However, our present data seem to indicate that ST3GAL6-AS1 expression levels are not significantly associated with clinical outcome and that its targeting may have antagonistic effects with proteasome inhibitors currently used in MM. This evidence concerns the gene ST3GAL6 and Miyoshi myopathy.